{"analyses":[{"ciLowerLimit":"0.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.71","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalComment":"Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \\> 2 years), and disease histology (FL, MZL).","statisticalMethod":"Stratified Log Rank Test"}],"classes":[{"categories":[{"measurements":[{"comment":"upper limit not available due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"43.0","upperLimit":"NA","value":"73.1"},{"groupId":"OG001","lowerLimit":"22.2","upperLimit":"39.4","value":"31.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"Time to next anti-lymphoma treatment (TTNLT) was defined as the time from date of randomization to date of first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy or immunotherapy). The time to the next anti-lymphoma treatment was of special interest to the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received rituximab 375 mg/m\\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \\< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.","id":"OG000","title":"Rituximab + Lenalidomide (R^2)"},{"description":"Participants received rituximab 375 mg/m\\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up to 12 cycles.","id":"OG001","title":"Rituximab + Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all participants who were randomized into the trial, regardless of whether they received study treatment or not.","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of first documented administration of a new anti-lymphoma treatment (Average of 55.71 months and a maximum up to 95.2 months)","title":"Kaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT)","type":"SECONDARY","unitOfMeasure":"Months"}